Onco Actu du 12 novembre 2018

	3.1 Prévention - Tabac
F.D.A. Plans to Seek a Ban on Menthol Cigarettes [NY Times] The proposal would have to go through the F.D.A. regulatory maze, and it could be several years before such a restriction took effect, especially if the major tobacco companies contest the agency’s authority to do so.
	3.4 Chimioprévention
Vitamin D And Fish Oil Supplements Mostly Disappoint In Long-Awaited Research Results [NPR] The trials involved nearly 26,000 healthy adults age 50 and older with no history of cancer or heart disease who took part in the VITAL research project. Twenty percent of the participants were African-American.
Vitamin D and Fish Oils Are Ineffective for Preventing Cancer and Heart Disease [NY Times] “In terms of preventing cancer, I think the door is closed. I don’t think there is anything there,” Dr. Rosen said.
	4.9 Dép., diag. & prono. - Sein
Breast screening linked to 60 per cent lower risk of breast cancer death in first 10 years [Queen Mary University of London] The research, using data from Sweden, finds that women who chose to participate in an organised breast cancer screening programme had a 60 per cent lower risk of dying from breast cancer within 10 years after diagnosis, and a 47 per cent lower risk of dying from breast cancer within 20 years after diagnosis.
Government funds trial of artificial intelligence to help with breast cancer screenings [The Telegraph] A grant has been given to London-headquartered technology start-up Kheiron Medical, which uses a form of AI named deep learning to process millions of mammograms.
	5.12 Immunothérapies
Radiotherapy-induced Responses Enhance the Efficacy of Anti-CTLA4 Therapy in Chemo-refractory Metastatic NSCLC [ESMO] Abscopal responses observed in tumours unresponsive to CTLA-4 blockade.
	5.12.3 Immunothérapies-combinaisons
The latest update on NKTR-214/Opdivo from Nektar and Bristol-Myers will keep the controversy burning over the ORR rate [EndPoints] Nektar Therapeutics managed to slide 1 out of its 38 evaluable stage 4 melanoma patients into the win column with its closely-watched 3-month update on Opdivo/NKTR-214’s objective response rate.
	5.12.9 Immunothérapies - SITC
New Data From Investigational Study Of Lenvima® (Lenvatinib) And Keytruda® (Pembrolizumab) Combination In Three Different Tumor Types Presented At The Society For Immunotherapy Of Cancer’s 33rd Annual Meeting [Eisai] New data support ongoing broad clinical program for LENVIMA and KEYTRUDA combination across multiple tumor types.
SITC18: Aduro finds some activity with STING agonist [FierceBiotech] The read-out raised questions about whether STING-targeted drugs used in humans will mirror the startling results seen in animal studies, and despite the glimmers of efficacy seen in the SITC study the jury is still out. The drugs are designed to kick-start an innate immune response against cancer cells in the tumor microenvironment.
Aduro Biotech Presents Preliminary Results from Ongoing Phase 1 Trials of STING agonist ADU-S100 (MIW815) in Patients with Advanced Solid Tumors or Lymphomas [Aduro] ADU-S100 is currently in a combination trial with investigational anti-PD-1 monoclonal antibody spartalizumab (PDR001) and with ipilimumab in an ongoing FIH study.
TESARO Announces Immuno-Oncology Data Presentations at SITC 2018 Annual Meeting [Tesaro] Initial data from AMBER trial of TSR-022 (anti-TIM-3) in combination with TSR-042 (anti-PD-1) demonstrated clinical activity in patients who have progressed following anti-PD-1 treatment.
SITC 2018 Scientific Highlights - Nov. 9 [SITC] The Society for Immunotherapy of Cancer (SITC) is pleased to present highlights from the first day of the 33rd Annual Meeting in Washington, D.C.
SITC 2018 Scientific Highlights - Nov. 10 [SITC] The Society for Immunotherapy of Cancer (SITC) is pleased to present scientific highlights from the Nov. 10, 2018, sessions of the 33rd Annual Meeting.
#SITC18: Another underwhelming performance for STING damages Aduro’s already suffering share price [EndPoints] The bottom line with STING is that mouse models appear to be entirely non-predictive.
	5.2 Pharma
US FDA accepts regulatory submission for Lynparza maintenance therapy in newly-diagnosed, BRCA-mutated advanced ovarian cancer and grants Priority Review [AstraZeneca] Approval would expand use of AstraZeneca and MSD’s Lynparza to patients in the 1st-line setting following platinum-based chemotherapy.
As Novartis' other cancer launches struggle, Lutathera gets off to flying start [FiercePharma] While Lutathera is just one of a few oncology approvals for Novartis as of late, its other two rollouts haven’t started off with the same bang. With Kisqali, a breast cancer treatment approved last March, Novartis has struggled to gain traction against Pfizer blockbuster Ibrance and newer rival Verzenio from Eli Lilly. And Kymriah, the company’s pioneering CAR-T drug, has run into manufacturing challenges that have slowed expansion.
	5.4 Traitements - Economie
Eisai's Lenvima wins over NICE in liver cancer in just three months [Pharmafile] The decision came quickly – just three months after EU approval – a stark contrast to the drug’s passage through the same system for the treatment of thyroid cancer, which took almost three years.
	6.3 Associations/Fondations
Billionaire gifts Harvard a historic $200M to ‘expedite’ translational biomedical research work [EndPoints] “The overarching goal of the gift is to accelerate the pace of therapeutic discovery by shortening the trajectory between basic discovery and transformation of insights into therapies,” Harvard Medical School wrote of the pledge, which is the largest in its 236-year history.
	6.6 Publications
Reaction of Researchers to Plan S: Too Far, Too Risky [Plan S Open Letter] Researchers should have the freedom to choose publication venue, and while complying with Open Access mandates to also choose how papers are made Open Access, in a way that contributes to minimal increased costs for the publishing system while not impinging on academic freedom or jeopardizing internationalization in research and higher education.
	6.7 DMP, Big Data & applis
Why Did Google Hire Geisinger CEO Dr. David Feinberg? [Forbes] In the past, Google’s motto was “don’t be evil.” Convincing patients they have nothing to fear by handing over their health information online, or allowing Google to obtain it from their home, will be a major hurdle.
	6.7.1 IA/bioinformatique
AI Doesn't Ask Why -- But Physicians And Drug Developers Want To Know [Forbes] Our most substantial challenge, I expect, will be figuring out how to wrap our heads around the core premise of AI – are we, as physicians, ready to receive and act on answers without even the pretense of explanation?
	6.9 Controverses
What’s in a p value? [Vantage] The fact is that a flawed understanding of statistics, common among some investors and probably a few biotech C-suites too, likely lies at the heart of the current malaise. The bald view that a certain p value – be it 0.05 or 0.005 – shows that the data are “good” is in itself fundamentally flawed. It is this ignorance that needs to be treated.